Skip to content

Effect of oscillating positive expiratory pressure treatment before or after long-acting inhaled drugs on patients with stable chronic obstructive pulmonary disease: a multicenter, randomized controlled study

Effect of oscillating positive expiratory pressure treatment before or after long-acting inhaled drugs on patients with stable chronic obstructive pulmonary disease: a multicenter, randomized controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100041627
Enrollment
Unknown
Registered
2021-01-01
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

RI:Using Long-acting inhalant before respiratory strengther
IR: Using Long-acting inhalant after respiratory strengther
C:Only Using Long-acting inhalant

Sponsors

The First Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Consistent with the diagnostic criteria for COPD or highly suspected to be COPD.Copd is defined as: (1) the clinical diagnosis of copd; (2) 1s forced expiratory volume (FEV 1)/ forced vital capacity (FVC)< 0.70. 2. Between the ages of 40 and 80, regardless of gender. 3. No history of acute exacerbation in the past 4 weeks. 4. Inhalation medication must be used correctly. 5. The patient must be able to complete the whole process of respiratory rehabilitation on his/her own.

Exclusion criteria

Exclusion criteria: 1. Other respiratory diseases (severe pneumothorax or pleural effusion without drainage, bronchiectasis and active hemoptysis). 2. Severe primary disease associated with other major organs or systems. Cancer (untreated tumor or tumor requiring treatment for the first two years).Fuo, instability of cardiovascular disease (cardiac arrhythmias (atrial flutter and fibrillation, frequent ventricular tachycardia, atrioventricular block) of ischemic heart disease, myocardial infarction, always 6 months), uncontrolled high blood pressure (systolic blood pressure 160 mmHg, or diastolic blood pressure, 90 mmHg or higher) (1 mmHg = 0.133 kPa), severe pulmonary hypertension, accompanied by organ failure. 3. Concomitant musculoskeletal disease, neurological disease, rheumatic connective tissue disease, vascular disease affects the assessment and completion of rehabilitation (presence of lumbar, back and/or limb dysfunction or post-operative status, severe arthritis or severe peripheral vascular disease, etc.). 4. Mental disorder or cognitive impairment. 5. Poor compliance or refusal to undertake rehabilitation training. 6. A history of lung surgery in the first three months. 7. Difficult transportation and language barriers. 8. In the past 12 months, there have been more than 4 emergency admissions for any reason. 9. Another experiment is taking place.Patients enrolled in other clinical studies or in this study were still within 6 half-lives of the previous study drug at the time of screening 1 month prior to screening. 10. Active period of various infectious diseases. 11. People who have participated in respiratory rehabilitation before, but do not include those who have had irregular respiratory rehabilitation. 12. Allergic to inhaled medications. 13. The oral glucocorticoid dose needs to be altered or stabilized but in excess of a dose equivalent to 10 mg/d prednisone. 14. Pregnant or lactating women or women of childbearing age do not use effective contraception. 15. A history of alcohol or drug dependence or is using alcohol or drugs. 16. History of post-exercise syncope or exercise contraindications.

Design outcomes

Primary

MeasureTime frame
6 minutes walking distance;

Secondary

MeasureTime frame
CAT questionnaire;CCQ questionnaire;BCSS questionnaire;Borg;Borg;acute exacerbation;survive;

Countries

China

Contacts

Public ContactZheng Zeguang

The First Affiliated Hospital of Guangzhou University of Medical

zheng862080@139.com+86 18928868242

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026